PDCD1 and cancer: The successful application of immune checkpoint inhibitors of anti‐PD‐1 and PD‐L1 (programmed cell death protein ligand‐1) has attracted considerable interest in the field of immuno‐oncology for a variety of advanced cancers.13, 14, 15